Sigma-1 receptors (Sig-1Rs) are integral ER membrane proteins. They bind diverse ligands, including psychoactive drugs, and regulate many signaling proteins, including the inositol 1,4,5-trisphosphate receptors (IP 3 Rs) that release Ca 2+ from the ER. The endogenous ligands of Sig-1Rs are unknown. Phospholipase D (PLD) cleaves phosphatidylcholine to choline and phosphatidic acid (PA), with PA assumed to mediate all downstream signaling. We show that choline is also an intracellular messenger. Choline binds to Sig-1Rs, it mimics other Sig-1R agonists by potentiating Ca 2+ signals evoked by IP 3 Rs, and it is deactivated by metabolism. Receptors, by stimulating PLC and PLD, deliver two signals to IP 3 Rs: IP 3 activates IP 3 Rs, and choline potentiates their activity through Sig-1Rs. Choline is also produced at synapses by degradation of acetylcholine. Choline uptake by transporters activates Sig-1Rs and potentiates Ca 2+ signals. We conclude that choline is an endogenous agonist of Sig-1Rs linking extracellular stimuli, and perhaps synaptic activity, to Ca 2+ signals.
In Brief
Sigma-1 receptors respond to diverse stimuli and regulate many signaling proteins. Brailoiu et al. show that choline is an endogenous agonist of Sigma-1 receptors. Choline links receptors and cholinergic synaptic activity, through Sigma-1 receptors, to enhanced Ca 2+ release through IP 3 receptors.
INTRODUCTION
The Sigma-1 receptor (Sig-1R) is a small integral membrane protein expressed mainly in the endoplasmic reticulum (ER) and concentrated at the dynamic contacts between mitochondria and ER, the mitochondria-associated ER membrane domains (MAMs) (Schmidt et al., 2016; Smith and Su, 2017; Su et al., 2016) . Sig-1R was thought to have two transmembrane domains (TMDs), with its N and C termini in the ER lumen (Aydar et al., 2002; Hayashi and Su, 2007) . This topology was consistent with evidence that BiP, an ER luminal chaperone protein, binds to the C-terminal domain of Sig-1R (Hayashi and Su, 2007) . However, a crystal structure of Sig-1R challenges these observations because it identified only a single TMD within each subunit of a trimeric complex, and it placed the C-terminal region on the cytosolic side of the ER membrane (Alon et al., 2017; Schmidt et al., 2016) .
Sig-1Rs are abundant in brain, but they are also expressed in other tissues (Smith and Su, 2017) . They are implicated in many pathologies, including depression, anxiety, amyotrophic lateral sclerosis and other neurodegenerative diseases, drug addiction, neuropathic pain, and cancers (Gueguinou et al., 2017; Su et al., 2016; Watanabe et al., 2016) . Sig-1Rs bind an unusually diverse array of ligands, most of which are amines. These include antidepressants (e.g., fluoxetine), antipsychotics (e.g., haloperidol), and drugs of abuse (e.g., cocaine and methamphetamine) (Maurice and Su, 2009; Walker et al., 1990) . Sig-1Rs also interact with many different signaling proteins. Within the ER, these proteins include inositol 1,4,5-trisphosphate receptors (IP 3 Rs) (Hayashi and Su, 2007) and STIM1, the Ca 2+ sensor for storeoperated Ca 2+ entry (Srivats et al., 2016) . At the plasma membrane (PM), Sig-1Rs regulate a variety of receptors and ion channels (Su et al., 2016) . Although many ligands of Sig-1Rs have opposing effects, their diversity and the many proteins that interact with Sig-1Rs confound attempts to classify ligands consistently as agonists or antagonists across all bioassays (Schmidt et al., 2016; Yano et al., 2018) . A more fundamental distinction may be whether ligands stabilize oligomeric (antagonists) or monomeric forms (agonists) of Sig-1R (Gromek et al., 2014; Mishra et al., 2015; Ossa et al., 2017; Schmidt et al., 2016; Yano et al., 2018) . Hence, agonists by releasing Sig-1Rs from large oligomeric complexes may free Sig-1Rs to interact with client proteins ( Figure 1A ). Several endogenous molecules, including steroids (Monnet and Maurice, 2006 ) (notably progesterone), various sphingolipids (Ramachandran et al., 2009) , and N,N-dimethyltryptamine (DMT) (Fontanilla et al., 2009 ), bind to Sig-1Rs and regulate some of their activities. It is unclear whether any of these ligands mediate endogenous regulation of Sig-1Rs, and none has been shown to link extracellular stimuli to regulation of Sig-1Rs. (Hayashi et al., 2000; Hong et al., 2004; Wu and Bowen, 2008) and to increase the efficiency of Ca 2+ transfer from ER to mitochondria through IP 3 Rs (Hayashi and Su, 2007; Shioda et al., 2012) .
Here, we demonstrate that agonists of G-protein-coupled receptors (GPCRs) that stimulate PLC and an increase in [Ca 2+ ] i , also stimulate phospholipase D (PLD). We show that choline produced by PLD is an endogenous agonist of Sig-1Rs, and that it thereby potentiates Ca 2+ signals evoked by IP 3 Rs. Each of the immediate products of choline metabolism, phosphocholine, acetylcholine, and betaine, is inactive. Hence, GPCRs signal to IP 3 Rs through two parallel pathways that converge to provide coincident stimulation of IP 3 Rs. In addition, choline uptake by specific transporters allows extracellular choline to stimulate Sig-1Rs and potentiate IP 3 -evoked Ca 2+ signals. We conclude that choline is an endogenous agonist of Sig-1Rs that links both cell signaling pathways (through PLD) and the activity of cholinergic synapses (through choline uptake) to regulation of IP 3 -evoked Ca 2+ signals.
RESULTS
Choline Binds to Sig-1Rs and Potentiates IP 3 -Evoked Ca 2+ Signals
Most high-affinity ligands of Sig-1Rs comprise a tertiary amine flanked by a short acyl chain and hydrophobic moieties (Glennon, 2005; Ossa et al., 2017) . Endogenous agonists are unlikely to have such high affinity because they must rapidly associate with and dissociate from Sig-1Rs if they are to acutely regulate them. We considered whether choline, a quaternary amine with an acyl chain but no hydrophobic moieties, might be an endogenous agonist of Sig-1Rs.
(+)-Pentazocine is a high-affinity, selective ligand of Sig-1Rs (equilibrium dissociation constant, K d = 5.5 nM) (de Costa et al., 1989) . Specific binding of [ 3 H](+)-pentazocine to membranes prepared from Neuro-2A cells stably expressing Sig-1R was completely displaced by choline (K i = 525 mM; pK i = 3.28 ± 0.16; h = 1.07 ± 0.2; mean ± SEM; n = 5; where pK i is the negative log of the K d , and h is the Hill coefficient) ( Figure 1B) . Phosphocholine, the major product of choline metabolism in most cells ( Figure 1C ) (Corbin and Zeisel, 2012) , did not displace specific [ 3 H](+)-pentazocine from Sig-1Rs, and the other immediate products of choline metabolism, betaine (K i = 1.32 mM; pK i = 2.88 ± 0.23; h = 1.40 ± 0.35; n = 5) and acetylcholine (K i $12 mM; n = 5), were less Figure S1A .
effective than choline. This is consistent with choline binding with greater affinity than its metabolites to the same site as known agonists and antagonists of Sig-1Rs. Subsequent experiments explore the interactions of choline with Sig-1Rs in NG108-15 cells. These neuroblastoma-glioma hybrid cells retain many properties of neurons, including responsiveness to neurotransmitters, and the ability to synthesize and release acetylcholine (Hamprecht et al., 1985) expression was reduced to 50% ± 12% of control levels by the shRNA treatment (mean ± SD; n = 3). ] i , whereas microinjection of choline or the Sig-1R agonist, (+)SKF-10047, had no effect. However, co-injection of choline or (+)SKF-10047 with IP 3 potentiated the IP 3 -evoked Ca 2+ signals (Figures 2A and 2B ). When applied to intact cells, neither choline nor other Sig-1R ligands significantly affected the Ca 2+ content of the intracellular stores (Figures S1B and S1C) . The potentiation of IP 3 -evoked Ca 2+ release by choline was blocked by pre-incubation with the Sig-1R antagonist, BD1047 ( Figure 2B ). Neither betaine, phosphocholine, nor acetylcholine mimicked the effects of microinjected choline ( Figures 2C and 2D ). Treatment of NG108-15 cells with appropriate short hairpin RNA (shRNA) reduced expression of Sig-1R ( Figure 2E ) and abolished the potentiating effects of choline and (+)SKF-10047, without affecting responses to IP 3 alone (Figures 2A and 2B ). In MCF7 breast cancer cells, Sig-1R expression was scarcely detectable ( Figure 2F ) (Wu and Bowen, 2008 Figure 3D ). We next considered whether the contribution of Sig-1Rs to the Ca 2+ signals evoked by GPCRs might be mediated by choline. Both mammalian isoforms of PLD (PLD1 and PLD2) are almost ubiquitously expressed enzymes that hydrolyse phosphatidylcholine (PC) to phosphatidic acid (PA) and choline. PLDs are regulated by many signals, including those that stimulate PLC and protein kinase C (PKC) (Selvy et al., 2011) .
The basal choline concentration in NG108-15 cells (144 ± 7 mM) was similar to values reported for other cells (100-400 mM) (Pelech and Vance, 1984) . Stimulation of NG108-15 cells with extracellular ATP increased the intracellular concentrations of both choline and IP 3 . Knockdown of PLD1 and PLD2 expression using shRNA ( Figure 3E ) prevented the increase in choline concentration without affecting IP 3 production ( Figures 3F and 3G) . Furthermore, the ATPevoked Ca 2+ signals were similarly and substantially attenuated by loss of Sig-1R or loss of PLDs ( Figures 3A-3C ).
The results so far demonstrate that GPCRs, by stimulating both PLC and PLD, generate parallel signals, IP 3 and choline, which converge to stimulate Ca 2+ release through IP 3 Rs ( Figure 3H ).
Choline Uptake Regulates Ca 2+ Signals Synthesis of acetylcholine within cholinergic nerve terminals requires choline uptake by a high-affinity, Na + -dependent transporter (CHT1 [choline high-affinity transporter 1]) expressed mostly at cholinergic terminals (Haga, 2014; Sarter and Parikh, 2005 cells are capable of high-affinity choline uptake and they express CTL1, but not CHT1 (Machová et al., 2009) , consistent with evidence that CTL1 is expressed in neurons and glia (Traiffort et al., 2013) . Incubation of NG108-15 cells with choline caused a timedependent increase in the amplitude of the Ca 2+ signals subsequently evoked by bradykinin ( Figure 4A ). The effect was minimally affected by removing the extracellular choline immediately before stimulation with bradykinin ( Figure S2) (Figures 4C-4E ). -mobilizing GPCRs stimulate PLC and PLD, with consequent formation of IP 3 and choline. Although we have not resolved how GPCRs stimulate PLD in NG108-15 cells, signals evoked by both PLC and parallel pathways are known to stimulate PLD. IP 3 stimulates IP 3 R, while choline binds to Sig-1Rs, causing them to potentiate IP 3 R activity. Metabolism of IP 3 and choline terminates their signaling. Hence, GPCRs regulate IP 3 Rs through two parallel, but converging, pathways. Import of extracellular choline by transporters, including the widely expressed CTL1, can also deliver choline to Sig-1Rs. (G) Acetylcholine (ACh) released at cholinergic terminals can activate post-and pre-synaptic receptors, before its rapid hydrolysis to choline by acetylcholinesterase (AChE). Hence, synaptic activity is rapidly followed by a substantial local increase in choline concentration. Transporters (red circles) in the cholinergic terminal (CHT1) and neighboring cells (CTL1-5 and OCT) can import the choline, which will then stimulate Sig-1Rs, providing cells with a paracrine reporter of recent synaptic activity. See also Figure S2 .
DISCUSSION
Sig-1Rs respond to many diverse drugs, including some that are commonly abused or used clinically, but it is unclear whether endogenous agonists regulate Sig-1Rs (Maurice and Su, 2009 ). Here, we provide evidence that choline ( Figure 1C) , best known as a precursor for synthesis of acetylcholine and PC, the most abundant membrane phospholipid in mammalian cells, is an endogenous agonist of Sig-1Rs. We show that choline meets the three essential criteria of an intracellular messenger, namely it is produced in response to extracellular stimuli, it exerts a specific intracellular action, and it is endogenously deactivated. We conclude that choline is an intracellular messenger linking GPCRs, through Sig-1Rs, to Ca 2+ release from intracellular stores ( Figure 4F ).
Choline mimicked known Sig-1R agonists by competing with (+)-pentazocine for binding to Sig-1Rs ( Figure 1B ) and by potentiating the Ca 2+ signals evoked by receptors that stimulate IP 3 formation (Figures 2A, 2B , and 2D). The immediate metabolites of choline were ineffective ( Figures 2C and 2D ). The effect of choline on Ca 2+ signals was attenuated when Sig-1R expression was reduced (Figures 2A, 2B , and 2E); and in cells without Sig1Rs, expression of Sig-1R endowed the cells with sensitivity to choline ( Figures 2F-2H ). The Ca 2+ signals evoked by GPCRs that stimulate formation of IP 3 were attenuated when Sig-1R expression was reduced ( Figures 3A-3D) . ATP, which stimulates PLC through P2Y 6 receptors in NG108-15 cells (Sak et al., 2001) , rapidly evoked formation of IP 3 and choline, but only the latter required PLDs (Figures 3F and 3G) . Furthermore, the ATPevoked Ca 2+ signals were similarly attenuated by loss of PLDs or Sig-1Rs ( Figure 3C ). Bradykinin-evoked Ca 2+ signals were likewise attenuated by loss of Sig-1Rs ( Figure 3D ).
Many GPCRs that stimulate PLC also activate PLD, and most agonists that activate PLD also stimulate PLC. However, the links between GPCRs and stimulation of mammalian PLD differ between cell types, and the stimulatory signals, which include PKC, Ca 2+ , small GTPases (rho and ADP-ribosylation factor [Arf]), phosphatidylinositol 4,5-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate, can be generated by PLC or parallel pathways (Exton, 1999; Selvy et al., 2011) . Hitherto, signaling downstream of PLD has been thought to arise entirely, directly or indirectly, from PA (Selvy et al., 2011). We suggest that the other product of PLD activity, namely choline, is also an important intracellular messenger that regulates Sig-1Rs and thereby IP 3 -evoked Ca 2+ release ( Figures 3H and 4G ). Our estimate of the intracellular choline concentration in NG108-15 cells after GPCR activation ($900 mM) ( Figure 3F ) is similar to that required for binding to Sig-1Rs (K i = 525 mM) ( Figure 1B) . The low affinity of choline, relative to the many ligands used to establish structureaffinity relationship for Sig-1R (Glennon et al., 1992) , is important because it will allow Sig-1R to respond rapidly to acute changes in intracellular choline concentration. We conclude that choline is an endogenous agonist of Sig-1Rs, a consequence of which includes potentiation of IP 3 -evoked Ca 2+ release ( Figure 3H ). Choline is an essential nutrient that cells import through transporters from plasma, where the choline concentration is typically 5-10 mM, although it varies with diet (Sarter and Parikh, 2005) . At cholinergic synapses, the choline concentration may be much higher ($1 mM) after synaptic activity, when acetylcholine is rapidly hydrolysed by acetylcholinesterase ( Figure 4G ). Our results show that extracellular choline, at concentrations encompassing likely synaptic concentrations, potentiates GPCRevoked Ca 2+ signals. The potentiation requires both Sig1R and the choline transporter, CTL1 ( Figures 4A-4E and S2 ). These observations suggest an additional signaling role, whereby changes in extracellular choline concentration might regulate Sig-1Rs and thereby Ca 2+ signaling. Such a mechanism might be particularly effective at cholinergic synapses of neuromuscular junctions or within the autonomic nervous system (Picciotto et al., 2012) , where rapid transient increases in choline concentration follow synaptic activity. Choline might then determine the sensitivity of adjacent neurons or glia to PLC-coupled GPCRs ( Figure 4G ), consistent with many reported interactions between Sig-1Rs and cholinergic transmission (van Waarde et al., 2011) . Hence, choline, as an endogenous agonist of Sig1Rs, may be both an intracellular messenger linking GPCRs through PLD to Sig-1Rs ( Figure 4F) ; and a paracrine signal at cholinergic synapses linking synaptic activity, through choline transporters, to Sig-1R regulation in nearby cells ( Figure 4G ). We conclude that choline is an endogenous agonist of Sig1Rs. Although we examined the consequences of activating Sig-1Rs only in the context of IP 3 -evoked Ca 2+ signals, it is likely that choline, like other agonists of Sig-1Rs, also promotes interaction of Sig-1Rs with other signaling proteins. We propose that choline may be delivered to Sig-1Rs as a paracrine reporter of activity at cholinergic synapses through choline transporters, or as an intracellular messenger from PLD activated by GPCRs ( Figures 4F and 4G ). The GPCRs that stimulate both PLC and PLD thereby send parallel signals to IP 3 Rs: IP 3 directly activates IP 3 Rs, while choline stimulates Sig-1Rs, which potentiate IP 3 R activity. IP 3 Rs thereby function as coincidence detectors, integrating signals from IP 3 and Sig-1Rs ( Figures 3G and 4F ).
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The NG108-15 cell line (ATCC) is a somatic hybrid derived from a mouse neuroblastoma and rat glioma. NG108-15 cells were grown in DMEM/F12 with 10% fetal bovine serum (FBS). MCF7 cells (ATCC) were derived from a human metastatic mammary tumor. These cells were grown in RPMI with 10% FBS. Neuro-2A cells (ATCC), which were used only for heterologous expression of Sig-1R-GFP for radioligand binding analyses, were derived from a mouse neuroblastoma. Neuro-2A cells were grown in DMEM containing 10% FBS, and further supplemented with G-418 (100 mg/mL) for the cells stably expressing Sig-1R-GFP. We have not established the sex of the animals from which NG108-15 and Neuro-2A cells were derived. All cells were grown in humidified air at 37 C with 5% CO 2 . Cells were passaged when they reached around 80% confluence. The authenticity of the cell lines was not confirmed, but screening established that all cells were free of mycoplasma.
METHOD DETAILS
Transfection of Cells Cells were transiently transfected using either TurboFectin 8.0 or electroporation. For the former, plasmid DNA was added to TurboFectin 8.0 in OptiMEM I (TurboFectin:DNA, 3:1), incubated (15-30 min, 20 C), and the complex was then added to cells in 6-well plates (1-1.5 mg DNA/well) in complete medium, and incubated for 24-48 h. For electroporation, cells (80%-90% confluent in a T75 flask) were scraped into culture medium, centrifuged (150 xg, 5 min), and resuspended in Opti-MEM I (2 3 10 6 cells/mL). Cells (500 mL) were transferred to electroporation cuvettes (800 mL, 4-mm gap; Eppendorf, Hamburg, Germany) with plasmid DNA (5-10 mg/cuvette) and the cells were subjected to electroporation using a GenePulser Xcell (BioRad, 200-250V, 700-900 mF, 18-20 ms). Transfected cells were plated in Opti-MEM I in 6-well plates, FBS (10%) was added after 4 h, and the medium was replaced after 24 h.
Neuro-2A cells stably expressing Sig-1R-GFP were generated by transfecting cells with plasmid encoding human Sig-1R-GFP using Lipofectamine. Cells were grown in medium containing G418 (400 mg/mL), and after 2 weeks resistant colonies were selected and propagated. Stable cell lines with intermediate levels of Sig-1R-GFP expression (determined by fluorescence microscopy) were identified and then maintained in DMEM supplemented with FCS (10%) and G418 (100 mg/mL).
For expression of human Sig-1R-GFP, cells grown in 6-well plates were transfected with 1-1.5 mg DNA/well. To reduce expression of Sig-1R or PLDs, RFP-tagged shRNA constructs were used. Each set of constructs included four different 29-mer targeting shRNA in a pRFP-C-RS plasmid. Using methods reported previously (Brailoiu et al., 2016) , we used western blotting to assess the ability of each individual construct to reduce expression of its target protein (Sig-1R, PLD1 or PLD2). The most effective shRNA construct from each set was used for the experiments described here. The constructs were used individually for Sig-1R knockdown (2 mg/mL) or as a pair for knockdown of PLD1 and PLD2 (1 mg/mL of each). The same scrambled RFP-shRNA construct (2 mg/mL) was used as a control for all shRNA analyses.
Lipofectamine RNAiMax was used to transfect cells simultaneously with three different siRNAs against CTL1 (50 nM of each) to reduce CTL1 expression. A siRNA with no known target in mammalian genomes (150 nM) was used as a control for the siRNA experiments (Silencer control, ThermoFisher). Cells were used 24-48 h after transfection.
Radioligand Binding
Membranes were prepared from Neuro-2A cells stably expressing Sig-1R-GFP (Wu and Bowen, 2008 ] i in single Fura-2-loaded cells grown on glass coverslips (#1.5, 25-mm diameter, Warner Instruments), cells were incubated with Fura-2 AM (5 mM, 45 min, 20 C) in Hanks' balanced salt solution (HBSS), washed 3 times, and incubated for a further 45 min before experiments (Brailoiu et al., 2009) . Fluorescence images (alternate excitation at 340 and 380 nm; emission at 510 nm) were acquired at 0.25 Hz using an inverted Nikon Eclipse Ti microscope with a Perfect Focus System and a CoolSnap HQ2 CCD camera (Photometrics Scientific). Images were acquired and analyzed using NIS-Elements AR 3.1 software (Nikon). After correction for background, determined from an area outside the cell, fluorescence ratios (F 340 /F 380 ) were calibrated to [Ca 2+ ] i (Grynkiewicz et al., 1985) . Injections were performed using Femtotips II, InjectMan N I2 and FemtoJet systems (Eppendorf) (Brailoiu et al., 2009 ). Pipettes were back-filled with intracellular solution (110 mM KCl, 10 mM NaCl, 20 mM HEPES, pH 7.2) (Guse et al., 1997) and appropriate drugs. The injection time was 0.4 s at 60 hPa with a compensation pressure of 20 hPa in order to inject $1% of the cell volume.
Measurement of Ca 2+ Signals in Cell Populations
For measurements of [Ca 2+ ] i in cell populations, confluent cultures of cells in 96-well plates were loaded with Fluo-8 by incubation with Fluo-8 AM (2 mM, 30 min, 20 C) in HEPES-buffered saline (HBS) supplemented with 0.02% pluronic acid. The medium was then replaced with HBS, and after 30 min at 20 C to allow de-esterification of the indicator, fluorescence was recorded using a FlexStation III plate-reader (MDS Analytical Devices, Wokingham, UK) (Konieczny et al., 2017; Tovey et al., 2006) . Fluorescence was captured and processed using SoftMax Pro software. All measurements were performed in HBS at 20 C. HBS comprised: 135 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl 2 , 1.5 mM CaCl 2 , 11.5 mM glucose, 11.6 mM HEPES, pH 7.3. Fluorescence was recorded at 1.44 s intervals, with excitation at 485 nm and emission at 525 nm. The minimal (F min , Ca 2+ -free indicator) and maximal (F max , Ca 2+ -saturated indicator) fluorescence values were determined from several parallel wells in each plate after addition of Triton X-100 (0.1%) with either BAPTA (10 mM, for F min ) or CaCl 2 (10 mM, for F max ). Fluorescence values (F) were then calibrated to [Ca 2+ ] i from:
The K D of fluo-8 was assumed to be 389 nM.
Measurements of Intracellular IP 3 and Choline Concentrations NG108-15 cells (10 10 cells) in HBSS (0.5 mL, 20 C) were stimulated with ATP and the reaction was terminated by addition of cold HClO 4 (1 mL, 0.75 M). After centrifugation (2000 3 g, 5 min, 4 C), the supernatant was removed, PBS (270 mL) was added, and the mixture was sonicated. After centrifugation (15,000 3 g, 10 min), assay kits were used to determine the amounts of choline (BioVision Inc.) and IP 3 (DiscoveRx) in the supernatant, according to the manufacturer's instructions. A volume of 2.5 pL for an NG108-15 cell (Rouzaire-Dubois and Dubois, 1997) was used to calculate intracellular concentrations of IP 3 and choline.
QUANTIFICATION AND STATISTICAL ANALYSIS
For analyses of radioligand binding results, each equilibrium competition-binding curve was fitted to a logistic equation (GraphPad Prism, version 5) , from which the half-maximal inhibitory concentration (IC 50 ) and Hill coefficient (h) were determined. The IC 50 value, [ 3 H](+)-pentazocine concentration (5 nM) and K d of (+)pentazocine for Sig-1R (5.5 nM) (de Costa et al., 1989 ) were used to calculate K i values (K i is the K d determined by equilibrium competition binding) (Cheng and Prusoff, 1973) . The negative logarithms of these individual K i values (pK i ) were pooled for statistical analysis. All results are presented as means ± SD or SEM, as appropriate, from n independent analyses. ANOVA, followed by Dunnett's, Bonferroni or Tukey tests, was used to evaluate differences between groups (GraphPad Prism, version 5). p < 0.05 was considered significant. The tests used are reported in the figure legends.
